

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vincent Ippolito
Date of last notice	9 January 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust
Date of change	15 January 2025
No. of securities held prior to change	<p>Vincent Peter Ippolito</p> <ul style="list-style-type: none"> 8,000,000 Fully Paid Ordinary Shares 16,000,000 Performance Rights (expiring 2 December 2029) <p>Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust</p> <ul style="list-style-type: none"> 10,801,644 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	Nil
Number disposed	3,800,000 Fully Paid Ordinary Shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.44 per Fully Paid Ordinary Share

<p>No. of securities held after the change</p>	<p>Vincent Peter Ippolito</p> <ul style="list-style-type: none"> 8,000,000 Fully Paid Ordinary Shares 16,000,000 Performance Rights (expiring 2 December 2029) <p>Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust</p> <ul style="list-style-type: none"> 7,001,644 Fully Paid Ordinary Shares
<p>Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small></p>	<p>Executive Chair Vince Ippolito recently exercised 8,000,000 Performance Rights (expiring 2 December 2029) into 8,000,000 fully paid ordinary shares and has subsequently sold 3,800,000 fully paid ordinary shares on-market. These transactions have allowed Mr Ippolito to increase his holding in the Company to 15,001,644 fully paid ordinary shares whilst funding the tax obligations for the exercise of the 8,000,000 Performance Rights. The sale of 3,800,000 fully paid ordinary shares represents approximately 12.2% of Mr Ippolito’s fully diluted holding in the Company (including a total of 16,000,000 Performance Rights expiring 2 December 2029).</p> <p>Mr Ippolito has no plans to sell any additional shares in the medium term other than to satisfy any tax obligations.</p> <p>Mr Ippolito remains firmly committed to leading Botanix Pharmaceuticals Ltd as the Company transitions into a revenue generating commercial stage pharmaceutical company.</p>

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<p>Detail of contract</p>	<p>N/A</p>
<p>Nature of interest</p>	<p>N/A</p>
<p>Name of registered holder (if issued securities)</p>	<p>N/A</p>
<p>Date of change</p>	<p>N/A</p>
<p>No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small></p>	<p>N/A</p>
<p>Interest acquired</p>	<p>N/A</p>
<p>Interest disposed</p>	<p>N/A</p>
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small></p>	<p>N/A</p>
<p>Interest after change</p>	<p>N/A</p>

Part 3 – +Closed period

For personal use only

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A